Oncology

The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.

Data from the phase 3 MK-3475A-D77 trial support the Japanese approval of subcutaneous pembrolizumab and berahyaluronidase alfa.

The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.

The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.

Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.

Global Burden of Disease data showed alcohol-attributable cancer deaths in the US doubled from 1990 to 2023, with liver cancer showing the steepest rise.

“Far and away, a unified electronic health record is the single use case that could benefit both patients and physicians most, and AI has the potential to help us achieve that,” said Margarita Racsa, MD, MPH.

How do we implement AI in a way that serves patients? Expert radiation oncologists discuss the crucial question.

According to Margarita Racsa, MD, MPH, patients coming in with AI-informed insights can be a double-edged sword for clinicians.

ASCO has issued a critical drug supply warning as some practices report just weeks of ifosfamide inventory remaining, with no direct substitute available.

Oncology experts discussed the wide-ranging benefits of exercise in oncology care, including enhanced treatment efficacy, minimal AEs, and minimal expenses.

Patients in US counties with the highest medical debt burden had higher odds of stage IV cancer diagnosis and worse survival than those in the lowest-burden counties.

City of Hope’s national clinical trials model can activate a study across a network of 40 sites in 4 states within 90 days, according to Edward Kim, MD, MBA.

ASCO 2026 spotlights metabolic health in cancer care, as GLP-1 obesity drugs show links to lower metastasis and survival gains, needing trials.

In a study, Black and Hispanic parents were largely willing to enroll children in oncology trials, while clinicians cited hardship and gatekeeping as barriers.

Frank McCormick, PhD, FRS, DSc (Hon), discussed his vision for preemptively treating KRAS-driven precancerous lesions, differences between KRAS allele subtypes, and where the field is headed over the next decade.

In part 1 of a 2-part interview, Frank McCormick, PhD, discusses the technical hurdles that made KRAS resistant to drug development, the NCI's RAS Initiative, and the RASolute 302 data.

No adverse effects or injuries associated with the presence of particulate matter in 3 lots of injectable cyclophosphamide have been reported to date.

Efficacy findings from the phase 1/2 LIBRETTO-001 and LIBRETTO-021 trials supported the regulatory approval of selpercatinib in RET gene fusion-positive solid tumors.

Jonathan Lee, MD, MSc, and Chinmay Jani, MD, have a candid conversation about what medical training actually feels like.

A primary driver of skyrocketing health care budgets has been the cost of prescription medications, which is particularly true for oncology, as personalized medicine is the standard of care.

A molecular residual disease test identified which patients with resected colorectal liver metastases gained a survival benefit from adjuvant chemotherapy.

ASCO Breakthrough 2026 spotlighted liquid biopsy, biomarkers, AI, and global equity, showing how data-driven precision oncology shapes personalized cancer care worldwide.

ASCO Breakthrough 2026 spotlights AI-driven tumor boards, trial matching, and MRD/ctDNA-guided therapy, signaling faster and more personalized cancer care.

ASCO Breakthrough 2026 spotlights ADCs, CAR-T, ctDNA-guided colorectal care and menin inhibitors driving precision cancer treatment.